The objective of this guide is to provide to nuclear medicine physicians a tool based on scientific evidence and prepared by consensus of experts, to perform the F-DCFPyL PET/CT procedure with safely and efficiently for patients with prostate cancer who present PSMA overexpression. For them, some recommendations will be established for F-DCFPyL PET/CT examination: reconstruction parameters, presentation of the images and their interpretation. The possible false positives of the procedure will be analysed, how to interpret them and how to avoid them. Finally, all exploration should lead to the preparation of a report that answers the clinician's question. For this, it is recommended to prepare a structured report that includes the PROMISE criteria as well as the classification of the findings according to PSMA-RADS parameters.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.remnie.2023.02.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study.
BMC Med Imaging
January 2025
Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, 030000, China.
Background: PSMA PET/CT emerges as a pivotal technology in the diagnostic landscape of prostate cancer (PCa). It offers a suite of imaging interpretation criteria, notably the maximum standardized uptake value (SUVmax), the molecular imaging prostate-specific membrane antigen score (miPSMA score), and the PSMA reporting and data system (PSMA-RADS). Identifying the most valuable criteria for diagnosing PCa and standardizing imaging interpretation across various tracers is an unresolved question.
View Article and Find Full Text PDFB-CLL with negative F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases.
EJNMMI Rep
January 2025
Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine & Endocrinology, University Hospital, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-radioligands is currently suggested by several clinical guidelines for the assessment of prostate cancer (PCa) in various clinical settings. However, PSMA will also be overexpressed in different cancers, which should be considered on the PSMA PET/CT reading in patients with concomitant neoplastic diseases. We report a case of 82-year-old male presented with prostate and history of oesophageal cancer and B-cell chronic lymphocytic leukemia (B-CLL).
View Article and Find Full Text PDFMediastinal lymph node metastases from prostate cancer: Enhanced diagnostic accuracy of PET/CT with F-DCFPyL versus F-choline.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
October 2024
Servicio de Medicina Nuclear, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
Clinical Factors Associated With Suspicious F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.
J Urol
February 2025
Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Purpose: There are limited data on prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT for workup of recurrence after radical prostatectomy (RP) at low PSA values. We evaluated a PSMA PET/CT cohort of patients post RP, focusing on patients with PSA < 0.5 ng/mL.
View Article and Find Full Text PDFPatterns of failure with F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis.
Can Urol Assoc J
October 2024
McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Introduction: This study aimed to assess the detection rate of prostate cancer recurrence by prostate-specific member antigen positron emission tomography/computed tomography (PSMA PET/CT) with F-DCFPyL in patients with residual disease or biochemical recurrence (BCR), and its association with surgical pathology and prostate-specific antigen (PSA) kinetics.
Methods: Men from South Central Ontario enrolled in the PSMA Registry for Recurrent Prostate cancer (PREP) between April 2019 and December 2021 after radical prostatectomy (RP) and who had 1) pathologic stage N1 or persistent elevated PSA; or 2) BCR (PSA >0.10 ng/mL) where initial postoperative PSA was undetectable were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!